Skip to content

Dietary Supplementation to Increase Serum Choline Levels

Dietary Supplementation to Increase Serum Choline Levels

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02403804
Enrollment
8
Registered
2015-03-31
Start date
2015-04-30
Completion date
2015-09-29
Last updated
2020-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Dietary supplements, serum choline, women

Brief summary

The goal is to assess whether, in adult women during the luteal phase of their menstrual cycle, supplementing their diet with either phosphatidylcholine or betaine increases their serum choline levels.

Detailed description

Elevated maternal serum free choline has the potential to improve fetal brain development . However, in humans, choline can be metabolized by gut flora into two metabolites with adverse outcomes: trimethylurea (which causes body odor) and Trimethylamine (TMA) which is then, once absorbed, metabolized into Trimethylamine-N-Oxide (TMAO). There is some concern that TMAO may be atherogenic and thus, if elevated over an extended period of time, may increase risk for cardiac disease. Thus, while maternal choline supplementation may improve fetal brain development, there is a potential for maternal adverse effects. However, humans have an active choline metabolic pathway, and other components of the choline metabolic pathway (e.g. phosphatidylcholine and betaine) may be interchangeable with choline post absorption but are resistant to gut bacteria metabolism (i.e. serum TMA does not increase). Thus, these other compounds would be expected to increase serum but with no impact on TMA or trimethylurea levels. An initial study of phosphatidylcholine supplementation in pregnant women was consistent with this hypothesis; infant offspring demonstrated improved cerebral inhibition; while no adverse events were identified for either mother or infant. Unfortunately, because of the lipid groups incorporated into phosphatidylcholine, its molecular weight is high and reasonable doses require consuming several large capsules a day. The study represents the first attempt to determine if betaine, an alternative compound within the same metabolic pathway but with a much lower molecular weight, also increases serum choline levels. As the first step, this proposal seeks to address this in non-pregnant women. Specifically, the goals are to (a) assess whether changes in serum choline levels in response to molar equivalent supplementation of phosphatidylcholine versus betaine are similar, and (b) whether, for betaine, there is a dose response relationship between supplementation dose and serum choline levels.

Interventions

DIETARY_SUPPLEMENTPhosphatidylcholine

Phosphatidylcholine 3600 mg qam and 2700 mg qpm

DIETARY_SUPPLEMENTBetaine (588 mg qam and 412 mg qpm)

Betaine anhydrous 588 mg qam and 412 mg qpm

DIETARY_SUPPLEMENTBetaine (1000 mg BID)

Betaine anhydrous 1000 mg BID

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. premenopausal 2. No nicotine use 3. No marijuana use 4. No illicit substance use 5. Weight \>= 90 pounds

Exclusion criteria

1. self-reported body odor of unknown etiology 2. personal or family history of cystathionine beta synthase deficiency (homocystinuria) 3. personal or family history of trimethylaminuria, renal or liver disease, Parkinson's disease

Design outcomes

Primary

MeasureTime frame
change in serum choline4 hours post supplement.- baseline

Secondary

MeasureTime frame
change in serum choline2 hours post supplementation.- baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026